NECTA, a phase 1 alliance, is a compelling example of how collaboration, outreach, and a patient-centric model have enabled equitable access to #phase1 trials across a state spanning 800,000 km. Listen here! @garvaninstitute.bsky.social

open.spotify.com/episode/0Hzx...

#ASCO25 - Lung Cancer with Dr. Ned McNamee

Lung Cancer treatment continues to improve, especially in small cell and targeted therapy. This week we explore practice changing trials at @ascocancer.bsky.social

open.spotify.com/episode/1vcJ...

In this episode, we unpack game-changing insights from @ascocancer.bsky.social with a spotlight on #breastcancer .

Trials discussed include the SERENA-6, DESTINY-Breast09, and INAVO120, revealing inavolisib’s triplet therapy response in PIK3CA-mutated cancers open.spotify.com/episode/1L4S...

@ascocancer.bsky.social Plenary - Part 1

Our first episode focuses on adjuvant atezolizumab in the colon cancer space and the use of perioperative durvalumab in the gastric cancer space. Both are interesting spaces and have the potential to be practice-changing.

open.spotify.com/episode/47rZ...

*NEW EPISODE - BLADDER CANCER*

This week, we explore muscle-invasive bladder cancer (MIBC). The first trial is VESPER, comparing two important chemotherapy regimens.

The second trial utilises immunotherapy in the perioperative landscape
open.spotify.com/episode/4CfU...

Inflammatory Breast Cancer is a rare, aggressive subtype of breast cancer. This week, we interview Dr Massimo Cristofinelli, as we dive deep into this and many other pertinent aspects of #breastcancer from @weillcornell.bsky.social. See link below!

open.spotify.com/episode/6U9r...

Our latest episode on metastatic HR #breastcancer has dropped. While the CDK phase three trials have all read out, all of these drugs bave benefits and drawbacks. Tune into another great listen! #cancer #oncology #mededucation @breastcancernow.bsky.social

open.spotify.com/episode/7e2H...

2025 has begun and OFTIM has a great year ahead! This week, we explore the best updates from the @sabcs.bsky.social in 2024, looking at immunotherapy preoperatively, novel ADCs, the role of trastuzumab deruxtecan in HER2 low, & so much more! #breastcancer #oncology

open.spotify.com/episode/1GNE...